Centrally Acting Antihypertensive Drugs. Present and Future

References

• Van Zwieten P. A., Thoolen MJMC, Timmermans PBMWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984; 6(suppl. 11)28–33
   Google Scholar
• Van Zwieten P. A., Thoolen MJMC, Timmermans PBMWM. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA clonidine and guanfacine. Hypertension 1984; 6: 11–28
   Google Scholar
• Van Zwieten P. A., Chalmers J. P. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther 1994; 8: 787–799
   PubMed Web of Science ®Google Scholar
• Van Zwieten P. A. Different types of centrally acting anti-hypertensive drugs. Eur. Heart J. 1989; 3: 121–133
   Google Scholar
• Van Zwieten P. A. Overview of α2-adrenoceptor agonists with a central action. Am. J. Cardiol. 1986; 57: 3E–5E
   Google Scholar
• Prichard BNC, Tomlinson B., Renondin J. C. Urapidil, a multiple action α-blocking drug. Am. J. Cardiol. 1989; 64: 11
   PubMedGoogle Scholar
• Van Zwieten P. A., Blauw G. J., van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol. Toxicol. 1992; 70(suppl. II)S17–S22
   Google Scholar
• Michel M. C., Ernsberger P. Keeping an eye on the I-site: imidazoline-preferring receptors. Trends Pharmacol. Sci. 1992; 13: 369–370
   PubMed Web of Science ®Google Scholar
• Hieble J. P., Ruffolo R. R. Imidazoline receptors: historical perspective. Fundam. Clin. Pharmacol. 1992; 6(suppl 1)7S–13S
   Google Scholar
• Prichard BNC. Clinical pharmacology of moxonidine. The I₁-imidazoline receptor agonist moxonidine: a new antihypertensive.2nd Edition., P. A. van Zwieten, C. A. Hamilton, S. Julius, BNC Prichard. Roy. Soc. Med. Press, London 1996; 31–47
   Google Scholar
• United Kingdom Working Party on rilmenidine. Rilmenidine in mild-to-moderate essential hypertension. Curr. Ther. Res. 1990; 1: 194–211
   Google Scholar
• Filastre J. P., Letac B., Galinier F., Le Bihan G., Schwartz J. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am. J. Cardiol. 1988; 61: 81
   Google Scholar
• Mitrovic V., Patyna W., Hüting J., Schlepper W. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc. Drugs Ther. 1991; 5: 967–972
   PubMed Web of Science ®Google Scholar
• Prichard BNC. Clinical experience with moxonidine. The I-₁imidazoline receptor agonist moxonidine: a new antihypertensive.2nd Edition., P. A. van Zwieten, C. A. Hamilton, S. Julius, BNC Prichard. Roy. Soc. Med. Press, London 1996; 49–77
   Google Scholar
• Eichstáudt H, Richter W., Báuder M. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc. Drugs Ther. 1989; 3(suppl. 2)583–587
   Google Scholar
• N'Guyen Van Cao S., Levy B., Slama R. Non-invasive study of cardiac structure and function after rilmenidine for essential hypertension. Am. J. Cardiol. 1988; 61: 72, D–75D.
   Google Scholar
• Frei M., Küster L. Gardosch von Krosigk Moxonidine and hydrochlorothiazide in combination: a synergistic antihyper-tensive effect. J. Cardiovasc. Pharmacol. 1994; 24(suppl. 1)S25–S28
   PubMedGoogle Scholar
• Fiorentini C., Guillet C., Guazzi M. A multicentre double-blind trial comparing rilmenidine 1 mg and hydrochlorothiazide in 244 patients. Arch. Mal. Coeur Vaiss. 1989; 82: 39–46
   PubMedGoogle Scholar
• Panfilov V., Morris A. D., Donelly R., Reid J. L. Comparative effects of rilmenidine and atenolol on tests of autonomic function and mental and dynamic exercise in patients with essential hypertension. J. Cardiovasc. Pharmacol. 1995; 26(suppl. 2)S44–S47
   Google Scholar
• Morrison P. J., Corcoran C., Vivet P. Effect of rilmenidine on alertness. JAMA (French ed.) 1990, special issue July 27-28
   Google Scholar
• Thoolen MJMC, Timmermans PBMWM, van Zwieten P. A. Withdrawal phenomena of some centrally acting antihypertensieve drugs in the rat. Brit. J. Clin. Pharmacol. 1983; 15: 491S–505S
   Google Scholar
• Crisp P., Faulds A. Moxonidine. Drugs 1992; 44: 993–1012
   PubMed Web of Science ®Google Scholar
• Rupp H., Maisch B., Brilla C. Drug withdrawal and rebound hypertension. Differential action of the central antihypertensieve drugs moxonidine and clonidine. Cardiovasc. Drugs Ther. 1996; 10(suppl. 1)251–262
   PubMedGoogle Scholar
• Kaan E. C., Brückner R., Frohly P., Tulp M., Scharer S. G., Ziegler D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc. Risk Fact. 1995; 5(suppl. 1)19–27
   Google Scholar
• Krentz A. J., Evans A. J. Selective imidazoline receptor agonists for metabolic syndrome. Lancet 1998; 351: 152–154
   PubMed Web of Science ®Google Scholar
• Ernsberger P., Koletsky R. J., Collinds L. A., Bedol B. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc. Drugs Ther. 1996; 10: 275–282
   PubMed Web of Science ®Google Scholar
• Rosen P., Ohly P., Gleichman H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J. Hypertens. 1997; 15(suppl. 1)S31–S38
   Google Scholar
• Manolis A. J., Olympics C., Sifaki M. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension 1995; 26: 719–724
   PubMed Web of Science ®Google Scholar
• Julius S. Sympathetic overactivity and the patho-physiology of coronary risk in hypertension. Cardiovasc. Risk Fact. 1995; 5(suppl. 1)2–10
   Google Scholar